Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DRUS !! ABOUT TO SEE COPPER !!
DRUS !! GOV,CONTRACTS UNDER A PENNY !!
DRUS !! <<===ONLY TAKES ONE GOOD ONE !
DRUS !! <===== DONT MISS THIS ONE !!
DRUS !! ON THE MOVE !!
TSOI ! NICE NEWS !
Clinical Stage Cancer Immunotherapy Biotechnology Company Files Patent Expanding Uses of its Pterostilbene Based Product Pipeline
via OTC PR WIRE -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI) announced today filing of a patent on recent data showing pterostilbene potently augments killing of breast cancer, prostate cancer, and ovarian cancer cells by ozone therapy.
The data are an extension of ongoing work at the Company seeking to identify means of enhancing the effects of pterostilbene administration for treatment of a variety of cancers, as well as enhancing the efficacy of existing cancer therapies.
Previously the Company has been granted United States Patent # 9,682,047 covering augmentation of immunotherapy efficacy using pterostilbene administration. Furthermore, the Company has developed NanoStilbene, a nanotechnology-based product that enhances optimal delivery of pterostilbene to tissue. In the current patent application, administration of ozone in conjunction with various concentrations of pterostilbene resulted in enhanced tumor cell killing, without killing of control, non-cancer cells.
"The ability of ozone gas to possess a selective ability to kill cancer cells compared to non-cancer cells has been known since the 1980 publication by Sweet et al in the prestigious peer-reviewed journal Science. Furthermore, peer-reviewed studies have demonstrated that ozone therapy can enhance cancer-killing effects of chemotherapy," said Timothy Dixon, President, and CEO of Therapeutic Solutions International. "By demonstrating potentiation of the cancer-killing effects of ozone therapy by pterostilbene, we anticipate initiating collaborations with international doctors studying the efficacy of this modality in the treatment of cancer."
Therapeutic Solutions International has performed clinical pharmacokinetic studies using NanoStilbene to deliver pterostilbene. The concentrations of pterostilbene that are found in the blood 4 hours after oral administration of NanoStilbene are sufficient to enhance the cancer-killing effect of ozone therapy based on data presented in the patent application.
"Pterostilbene is known to kill cancer cells in part through increasing endoplasmic reticulum stress selectively in tumors and not in healthy cells. Our hypothesis was that ozone therapy may alter endoplasmic reticulum-associated molecular pathways, and thus a synergistic effect may be observed," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "By understanding molecular mechanisms of 'alternative medicines' such as ozone therapy, we can identify ways of leveraging their effects and developing therapeutic approaches that have higher chances of success."
"Numerous physicians internationally are using ozone therapy and other means of oxidative medicine to treat chronic illness. Although techniques such as autohemotherapy have a very strong safety record, little work is being conducted at elucidating mechanisms of action and identifying ways of integrating these approaches into conventional cancer care," said Dr. Juergen Winkler, Member of the Company's Scientific Advisory Board and Medical Director of Quantum Functional Medicine. "The medical doctors and scientists at Therapeutic Solutions International are leading the way in developing scientific understanding for molecular mechanisms of alternative medical immunotherapies in an objective and rigorous manner. By combining alternative medicine with cutting edge science, I am eager to watch the proper clinical trial translation that TSOI has performed in taking these concepts from bench to bedside."
About Therapeutic Solutions International, Inc.
DRUS !! NEWS COMING ALL WEEK !! Hammer candle friday get loaded here !
DRUS ! Today the $716 billion defense bill gets signed!!!!
Huge for DRUS since we already have contracts with the government.
https://www.google.com/amp/s/www.military.com/daily-news/2018/08/08/trump-visit-fort-drum-sign-national-defense-authorization-act.html/amp
DRUS !! WHY SUCH CHITTY CHARTS ?? I mean there so blah ....gl
DRUS !! <===BETTER GET YOUR SHARES ---ALL I CAN SAY !!......gl
DRUS !! UNDER A PENNY WITH GOV CONTRACTS !!
DRUS !! <=====ONLY TAKES ONE GOOD ONE !!
DRUS !! ON THE MOVE !
DRUS ! NEWS !
OTCQB Certification
I, MICHAEL BANNON, CEO of DRONE USA INC. (“the Company”), certify that:
a. The Company is registered or required to file periodic reporting with the SEC or is exempt from SEC
registration as indicated below (mark the box below that applies with an “X”):
[X] Company is registered under Section 12(g) of the Exchange Act
[ ] Company is relying on Exchange Act Rule 12g3-2(b)
[ ] Company is a bank that reports to a Bank Regulator under Section 12(i) of the Exchange Act
[ ] Company is a bank that is non-SEC reporting but is current in its reporting to a Banking Regulator
[ ] Company is reporting under Section 15(d) of the Exchange Act.
[ ] Company is reporting under the Alternative Reporting Company Disclosure Guidelines
[ ] Other (describe)
b. The Company is current in its reporting obligations as of the most recent fiscal year end and any subsequent
quarters, and such information has been posted either on the SEC’s EDGAR system or the OTC Disclosure &
News Service, as applicable.
c. The Company Profile displayed on www.otcmarkets.com is current and complete as of 12/20/2017 and includes
the total shares outstanding, authorized, and in the public float as of that date.
d. The company is duly organized, validly existing and in good standing under the laws of State of Delaware in
which the Company is organized or does business.
e. Identify any law firm and attorney(s) that acted as the Company’s primary legal counsel in preparing its most
recent annual report. Include the firm and attorney(s) name if outside counsel, or name and title if internal counsel.
(If no attorney assisted in putting together the disclosure, the Company must identify the person or persons who
prepared the disclosure and their relationship to the company.)
ERNEST STERN
CULHANE & MEADOWS PLLC
1101 PENNSYLVANIA AVENUE. N.W.
SUITE 600
WASHINGTON D.C.
f. The following is a complete list of third party providers, including names and addresses, engaged by the
Company, its officers, directors or controlling shareholders, during the period from the Company’s prior fiscal year
end to the date of this OTCQB Certification, to provide investor relations services, public relations services,
marketing or other related services to the Company. Please include providers engaged to promote the Company or
its securities.
UPTICK NEWS WIRE
g. The following is a complete list of Officers, Directors and Control Persons (control persons are beneficial owners
of more than five percent (5%) of any class of the issuer’s equity securities), including name, address, and percent
of shares owned. If any of the beneficial shareholders are corporate entities, provide the name and address of the
person(s) owning or controlling such corporate entities.
Name Address (City and State only) % Shares Owned
MICHAEL BANNON MIFORD CT 89
DAVID WILLIAMS LONG BEACH, NJ 0
RODRIGO KUNTZ MOGI DAS CRUZES,
BRAZIL
0
DRUS ! NEWS !
OTCQB Certification
I, MICHAEL BANNON, CEO of DRONE USA INC. (“the Company”), certify that:
a. The Company is registered or required to file periodic reporting with the SEC or is exempt from SEC
registration as indicated below (mark the box below that applies with an “X”):
[X] Company is registered under Section 12(g) of the Exchange Act
[ ] Company is relying on Exchange Act Rule 12g3-2(b)
[ ] Company is a bank that reports to a Bank Regulator under Section 12(i) of the Exchange Act
[ ] Company is a bank that is non-SEC reporting but is current in its reporting to a Banking Regulator
[ ] Company is reporting under Section 15(d) of the Exchange Act.
[ ] Company is reporting under the Alternative Reporting Company Disclosure Guidelines
[ ] Other (describe)
b. The Company is current in its reporting obligations as of the most recent fiscal year end and any subsequent
quarters, and such information has been posted either on the SEC’s EDGAR system or the OTC Disclosure &
News Service, as applicable.
c. The Company Profile displayed on www.otcmarkets.com is current and complete as of 12/20/2017 and includes
the total shares outstanding, authorized, and in the public float as of that date.
d. The company is duly organized, validly existing and in good standing under the laws of State of Delaware in
which the Company is organized or does business.
e. Identify any law firm and attorney(s) that acted as the Company’s primary legal counsel in preparing its most
recent annual report. Include the firm and attorney(s) name if outside counsel, or name and title if internal counsel.
(If no attorney assisted in putting together the disclosure, the Company must identify the person or persons who
prepared the disclosure and their relationship to the company.)
ERNEST STERN
CULHANE & MEADOWS PLLC
1101 PENNSYLVANIA AVENUE. N.W.
SUITE 600
WASHINGTON D.C.
f. The following is a complete list of third party providers, including names and addresses, engaged by the
Company, its officers, directors or controlling shareholders, during the period from the Company’s prior fiscal year
end to the date of this OTCQB Certification, to provide investor relations services, public relations services,
marketing or other related services to the Company. Please include providers engaged to promote the Company or
its securities.
UPTICK NEWS WIRE
g. The following is a complete list of Officers, Directors and Control Persons (control persons are beneficial owners
of more than five percent (5%) of any class of the issuer’s equity securities), including name, address, and percent
of shares owned. If any of the beneficial shareholders are corporate entities, provide the name and address of the
person(s) owning or controlling such corporate entities.
Name Address (City and State only) % Shares Owned
MICHAEL BANNON MIFORD CT 89
DAVID WILLIAMS LONG BEACH, NJ 0
RODRIGO KUNTZ MOGI DAS CRUZES,
BRAZIL
0
DRUS !! <====ONLY TAKES ONE GOOD ONE !!
DRUS !! ABOUT TO GO GREEN !!
DRUS !! SAR FLIPPING ON 30 MIN HERE !!
DRUS !! GOV , CONTRACTS !
DRUS !! ALOT A NEWS TO COME NEXT WEEK !!
DRUS !! ALOT A NEWS TO COME NEXT WEEK !!
DRUS !! BUYING LIKE CRAZY DOWN HERE !
AAPH !! GAP-FILLED ON THE MOVE !!
AAPH !! BLOWING-UP !!
AAPH !! BLOWING-UP !!
AAPH !! ?? WTF ??
CEI !! 8-K -OUT !
DRUS !! GOING GREEN GOV CONTRACTS !!
DRUS !! GOING GREEN GOV CONTRACTS !!
CELZ !! <====DONT MISS THIS ONE !!
CELZ !! <====BUY A GOOD ONE !!
UHLN !! SAR JUST FLIPPED ON 30 MIN !!
FRFS !! WHATS-UP ?
CELZ !! BREAKS .051 GAME-ON !!
CELZ !! ON THE MOVE !!
DRUS !! VOLUME PICKING-UP !!
TSOI !! CELZ !! <===SISTERS...SAME DOCTORS !!
CELZ !! NEWS SOON !!
TSOI ! NICE NEWS ! Oceanside, CA -- August 6, 2018 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today successful production of a stable microemulsion of Alpha Lipoic Acid (ALA) from ingredients Generally Regarded as Safe (GRAS). The microemulsion, which is a form of racemic alpha lipoic acid containing microparticles of ALA, is an ingredient in the Company's issued U.S. Patent No.: 9,682,047 along with pterostilbene, the active ingredient in the Company's patented ProJuvenol product.
Like pterostilbene, ALA is a very potent anti-oxidant and is also known as -lipoic acid, alpha lipoic acid (ALA) and thioctic acid, an organosulfur compound derived from octanoic acid and appears to be an ideal substance in the treatment of oxidative brain and neural disorders involving free radical processes. Thiols like ALA are central to antioxidant defense in brain and other tissues.
It is believed that Reactive Oxygen Species (ROS) are involved in many different types of pathologic conditions in the brain and neural tissue. Brain disorders involving free radical injury have few neuropharmacological intervention strategies for treatment of these conditions. ALA as a potent antioxidant, can regenerate through redox cycling other potent antioxidants like vitamin C and vitamin E, and to raise intracellular glutathione levels. The most important thiol antioxidant, glutathione, cannot be directly administered, whereas alpha lipoic acid can.
"There are numerous publications showing promising effects of alpha lipoic acid in preclinical models of neurodegenerative conditions such as multiple sclerosis1,2, stroke3,4, and Alzheimer's Disease5" said James Veltmeyer, MD, Chief Medical Officer of Therapeutic Solutions International. "By providing alternative delivery mechanisms of this agent, we believe we may be offering novel approaches towards addressing these terrible conditions."
"Treatment of chronic neurodegenerative conditions require a multi-factorial approach that addresses various molecular pathologies involved in the condition" added Tim Dixon, CEO of Therapeutic Solutions International. "By providing novel formulations capable of augmenting delivery of agents across the blood brain barrier, we aim to provide physicians new tools in their arsenal in treatment of conditions such as multiple sclerosis, Alzheimer's and post-stroke recovery."
About Therapeutic Solutions International, Inc.
The Company's corporate website is www.therapeuticsolutionsint.com. Our new products can be viewed on www.projuvenol.com and products can be ordered at www.youcanordernow.com.
These Supplement products have not been evaluated by the United States Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any diseases.
1 Dietrich et al. Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model. J Neuroinflammation. 2018 Mar 7;15(1):71. https://www.ncbi.nlm.nih.gov/pubmed/29514678
2 Khalili et al. Effect of alpha-lipoic acid on asymmetric dimethylarginine and disability in multiple sclerosis patients: A randomized clinical trial. Electron Physician. 2017 Jul 25;9(7):4899-4905. https://www.ncbi.nlm.nih.gov/pubmed/28894553
3 Wang et al. The Role of Alpha-Lipoic Acid in the Pathomechanism of Acute Ischemic Stroke. Cell Physiol Biochem. 2018 Jul 11;48(1):42-53. https://www.ncbi.nlm.nih.gov/pubmed/29996116
4 Choi et al. Alpha-lipoic acid treatment is neurorestorative and promotes functional recovery after stroke in rats. Mol Brain. 2015 Feb 11;8:9. https://www.ncbi.nlm.nih.gov/pubmed/25761600
5 Hager et al. Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis. J Neural Transm Suppl. 2007;(72):189-93. https://www.ncbi.nlm.nih.gov/pubmed/17982894
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
CLAYPLAYER !! PLEASE GET SO LOST NOT NEEDED EFFECT PEENNIES REALLY !! you really need to think about what your doing ...god !!